IN2014DN07888A - - Google Patents
Info
- Publication number
- IN2014DN07888A IN2014DN07888A IN7888DEN2014A IN2014DN07888A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A IN 7888DEN2014 A IN7888DEN2014 A IN 7888DEN2014A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A
- Authority
- IN
- India
- Prior art keywords
- nanostructures
- cells
- compositions
- cases
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Ceramic Engineering (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261601706P | 2012-02-22 | 2012-02-22 | |
PCT/US2013/027431 WO2013126776A1 (en) | 2012-02-22 | 2013-02-22 | Nanostructures for treating cancers and other conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN07888A true IN2014DN07888A (pt) | 2015-04-24 |
Family
ID=47833440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7888DEN2014 IN2014DN07888A (pt) | 2012-02-22 | 2013-02-22 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150064255A1 (pt) |
EP (2) | EP3597209A1 (pt) |
JP (1) | JP2015513543A (pt) |
KR (1) | KR20140123597A (pt) |
CN (1) | CN104244965A (pt) |
AU (1) | AU2013222238A1 (pt) |
CA (1) | CA2865279C (pt) |
ES (1) | ES2745208T3 (pt) |
IN (1) | IN2014DN07888A (pt) |
MX (1) | MX2014010161A (pt) |
WO (1) | WO2013126776A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006241123B2 (en) | 2005-04-25 | 2013-10-03 | Massachusetts Institute Of Technology | Compositions and methods for promoting hemostasis and other physiological activities |
DK2012842T3 (en) | 2006-04-25 | 2018-05-28 | Massachusetts Inst Technology | COMPOSITIONS AND PROCEDURES TO INFLUENCE THE MOVEMENT OF CONTAMINANTS, BODIES, OR OTHER UNITS AND / OR TO INFLUENCE OTHER PHYSIOLOGICAL CONDITIONS |
EP2288336B8 (en) | 2008-04-25 | 2017-03-22 | Northwestern University | Nanostructures suitable for sequestering cholesterol |
US9439941B2 (en) | 2009-12-14 | 2016-09-13 | The University Of Hong Kong | Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells |
AU2011207563B2 (en) | 2010-01-19 | 2016-03-10 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
EP2946014A2 (en) | 2013-01-17 | 2015-11-25 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
JP6697384B2 (ja) | 2013-07-25 | 2020-05-20 | イグジキュア, インコーポレーテッドExicure, Inc. | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 |
WO2015023797A1 (en) * | 2013-08-13 | 2015-02-19 | Northwestern University | Lipophilic nanoparticles for drug delivery |
US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
WO2016011049A2 (en) * | 2014-07-14 | 2016-01-21 | Schwendeman Anna | Compositions and methods for disease treatment using nanoparticle delivered compounds |
AU2015328242A1 (en) | 2014-10-06 | 2017-04-27 | Exicure, Inc. | Anti-TNF compounds |
US10517924B2 (en) * | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
WO2016123365A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
MX2017012131A (es) | 2015-03-25 | 2018-06-15 | Univ Michigan Regents | Composiciones y métodos para la administración de agentes de biomacromoléculas. |
US10967072B2 (en) | 2016-04-27 | 2021-04-06 | Northwestern University | Short interfering RNA templated lipoprotein particles (siRNA-TLP) |
EP3914236A4 (en) * | 2019-01-24 | 2022-10-26 | Northwestern University | HIGH-DENSITY LIPOPROTEINMIMETIC NANOPARTICLES USING LIPID-CONJUGATED CORE SCAFFOLDINGS |
EP3958843A4 (en) * | 2019-04-26 | 2023-02-22 | Northwestern University | HIGH DENSITY LIPOPROTEIN NANOPARTICLES AND RNA MATRIX LIPOPROTEIN PARTICLES FOR OCULAR THERAPY |
WO2020231860A1 (en) * | 2019-05-10 | 2020-11-19 | Northwestern University | Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses |
WO2021055788A1 (en) * | 2019-09-18 | 2021-03-25 | Northwestern University | High density lipoprotein-like nanoparticles as inducers of ferroptosis in cancer |
CN112569207A (zh) * | 2019-09-30 | 2021-03-30 | 复旦大学 | 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途 |
KR102614058B1 (ko) * | 2022-06-13 | 2023-12-15 | (주) 멥스젠 | 약물전달용 재구축 고밀도 지단백 나노입자 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1986699A4 (en) * | 2006-01-26 | 2010-12-15 | Univ Massachusetts | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE |
CA2708719A1 (en) * | 2007-12-12 | 2009-06-18 | University Health Network | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
EP2288336B8 (en) | 2008-04-25 | 2017-03-22 | Northwestern University | Nanostructures suitable for sequestering cholesterol |
AU2011207563B2 (en) * | 2010-01-19 | 2016-03-10 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
-
2013
- 2013-02-22 US US14/380,406 patent/US20150064255A1/en not_active Abandoned
- 2013-02-22 KR KR1020147025926A patent/KR20140123597A/ko not_active Application Discontinuation
- 2013-02-22 CN CN201380017827.7A patent/CN104244965A/zh active Pending
- 2013-02-22 AU AU2013222238A patent/AU2013222238A1/en not_active Abandoned
- 2013-02-22 CA CA2865279A patent/CA2865279C/en active Active
- 2013-02-22 MX MX2014010161A patent/MX2014010161A/es unknown
- 2013-02-22 WO PCT/US2013/027431 patent/WO2013126776A1/en active Application Filing
- 2013-02-22 ES ES13708044T patent/ES2745208T3/es active Active
- 2013-02-22 JP JP2014558893A patent/JP2015513543A/ja active Pending
- 2013-02-22 EP EP19175659.2A patent/EP3597209A1/en active Pending
- 2013-02-22 EP EP13708044.6A patent/EP2817024B1/en active Active
- 2013-02-22 IN IN7888DEN2014 patent/IN2014DN07888A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2865279C (en) | 2023-04-25 |
CA2865279A1 (en) | 2013-08-29 |
KR20140123597A (ko) | 2014-10-22 |
EP2817024B1 (en) | 2019-07-10 |
ES2745208T3 (es) | 2020-02-28 |
JP2015513543A (ja) | 2015-05-14 |
WO2013126776A1 (en) | 2013-08-29 |
AU2013222238A1 (en) | 2014-09-18 |
US20150064255A1 (en) | 2015-03-05 |
EP2817024A1 (en) | 2014-12-31 |
EP3597209A1 (en) | 2020-01-22 |
MX2014010161A (es) | 2015-03-09 |
CN104244965A (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN07888A (pt) | ||
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
UA99839C2 (ru) | Бензодиазепиноновые соединения, применяемые при лечении кожных состояний | |
MX359327B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
MY162903A (en) | Methods of treatment of pancreatic cancer | |
PH12015500879A1 (en) | Compositions and methods for treating proteinopathies | |
EP3587558A3 (en) | Methods of populating a gastrointestinal tract | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
IN2015KN00414A (pt) | ||
PE20150223A1 (es) | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos | |
SG10201808661XA (en) | Method of treating obesity using antioxidant inflammation modulators | |
MX362185B (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
MX2012010434A (es) | Compuestos y composiciones novedosas para atacar a las celulas madre del cancer. | |
GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
WO2010132697A3 (en) | Methods and compositions for treatment | |
WO2012170947A3 (en) | Methods for modulating factor 12 expression | |
IN2014CN03610A (pt) | ||
DK2714888T3 (da) | Rekombinant gær | |
MX365392B (es) | Composición de combinación de pac-1 y doxorrubicina. | |
MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
MX366380B (es) | Composiciones prebioticas para el cuidado oral que contienen un alquilglucosido. |